COPD association and repeatability of blood biomarkers in the ECLIPSE cohort.

PubWeight™: 1.43‹?› | Rank: Top 5%

🔗 View Article (PMC 3247194)

Published in Respir Res on November 04, 2011

Authors

Jennifer A Dickens1, Bruce E Miller, Lisa D Edwards, Edwin K Silverman, David A Lomas, Ruth Tal-Singer, Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators

Author Affiliations

1: Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK.

Associated clinical trials:

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE) | NCT00292552

Articles citing this

Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax (2012) 1.23

Systemic Inflammation in Older Adults With Asthma-COPD Overlap Syndrome. Allergy Asthma Immunol Res (2014) 1.10

Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08

Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res (2012) 1.07

Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One (2012) 1.03

Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One (2012) 1.02

Genome-wide association study of lung function phenotypes in a founder population. J Allergy Clin Immunol (2013) 0.97

Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulm Med (2012) 0.96

Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls. Int J Chron Obstruct Pulmon Dis (2015) 0.96

Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clin Transl Med (2016) 0.84

Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. ScientificWorldJournal (2014) 0.84

Utility of the CAT in the therapy assessment of COPD exacerbations in China. BMC Pulm Med (2014) 0.84

Association of biomarkers of inflammation and cell adhesion with lung function in the elderly: a population-based study. BMC Geriatr (2013) 0.83

Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Inflammation (2015) 0.83

Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study. J Inflamm (Lond) (2015) 0.82

Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values. Exp Ther Med (2016) 0.81

Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol (2014) 0.81

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med (2013) 0.80

Biomarkers in chronic obstructive pulmonary disease: confusing or useful? Int J Chron Obstruct Pulmon Dis (2014) 0.80

Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.80

Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res (2014) 0.79

Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.79

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation. Respir Res (2014) 0.78

Preserved function and reduced angiogenesis potential of the quadriceps in patients with mild COPD. Respir Res (2014) 0.78

Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. Am J Respir Crit Care Med (2016) 0.78

Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls. Int J Chron Obstruct Pulmon Dis (2016) 0.77

Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease. Exp Ther Med (2014) 0.76

High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. Respir Res (2016) 0.76

The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease. Qatar Med J (2016) 0.76

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75

The association between risk of airflow limitation and serum uric acid measured at medical health check-ups. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients. PLoS One (2016) 0.75

The PROTECCT-M study: a cohort study investigating associations between novel specific biomarkers, patient-related, healthcare system markers and the trajectory of COPD patients treated in primary care. BMC Pulm Med (2014) 0.75

Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory? BMC Pulm Med (2016) 0.75

A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects. BMJ Open Respir Res (2016) 0.75

Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease. J Occup Health (2016) 0.75

Articles cited by this

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Adjusting for multiple testing--when and how? J Clin Epidemiol (2001) 8.85

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax (1999) 8.63

Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J (2003) 6.23

Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38

Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 5.17

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53

Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med (2009) 4.27

Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest (2002) 3.82

C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69

Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51

Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80

Systemic inflammation and COPD: the Framingham Heart Study. Chest (2007) 2.74

Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost (2000) 2.74

C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax (2005) 2.72

Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax (2008) 2.25

Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol (2002) 2.10

Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest (2004) 2.08

Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J (2006) 1.94

Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2005) 1.85

Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res (2010) 1.79

Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 1.78

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75

Myeloperoxidase. Proc Assoc Am Physicians (1999) 1.72

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.70

Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62

Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax (2007) 1.61

Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J (2009) 1.56

COPD, a multicomponent disease: implications for management. Respir Med (2005) 1.36

Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med (2009) 1.26

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.23

Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res (2011) 1.20

An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med (1998) 1.20

Elevated circulating plasma adiponectin in underweight patients with COPD. Chest (2007) 1.17

Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung (2008) 1.16

Increased systemic inflammation is a risk factor for COPD exacerbations. Chest (2008) 1.12

Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 1.11

Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. Respir Med (2009) 1.03

Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax (2008) 1.01

The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis (2009) 0.98

Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol (2008) 0.98

Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers (2009) 0.97

Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother (2000) 0.95

All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest (2003) 0.94

"Fit-for-purpose" method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J (2009) 0.88

The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study. Ther Adv Respir Dis (2009) 0.84

Pulmonary and systemic hepatocyte and keratinocyte growth factors in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2008) 0.79

Articles by these authors

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93

Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69

Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57

Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54

Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92

Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75

PBAT: tools for family-based association studies. Am J Hum Genet (2004) 4.68

Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98

MMP12, lung function, and COPD in high-risk populations. N Engl J Med (2009) 3.96

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 3.92

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91

A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78

Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58

A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics (2003) 3.52

Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44

Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet (2009) 3.41

On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32

Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30

The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med (2007) 2.91

Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med (2004) 2.62

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol (2006) 2.49

The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet (2005) 2.46

Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am J Respir Crit Care Med (2003) 2.39

Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol (2007) 2.35

The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet (2007) 2.35

The clinical features of the overlap between COPD and asthma. Respir Res (2011) 2.29

Association of vitamin D receptor gene polymorphisms with childhood and adult asthma. Am J Respir Crit Care Med (2004) 2.24

Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet (2012) 2.24

The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet (2004) 2.19

Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem (2009) 2.19

Using the noninformative families in family-based association tests: a powerful new testing strategy. Am J Hum Genet (2003) 2.18

A family-based association test for repeatedly measured quantitative traits adjusting for unknown environmental and/or polygenic effects. Stat Appl Genet Mol Biol (2004) 2.15

Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med (2014) 2.14

Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet (2004) 2.14

Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med (2002) 2.11

Assessing the reproducibility of asthma candidate gene associations, using genome-wide data. Am J Respir Crit Care Med (2009) 2.10

Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers. Am J Respir Crit Care Med (2013) 2.09

Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol (2005) 2.08

A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07

Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2013) 2.06

Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med (2011) 2.06

Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet (2002) 2.02

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99

A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98

Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98

Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94

A new powerful non-parametric two-stage approach for testing multiple phenotypes in family-based association studies. Hum Hered (2003) 1.89

Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica. J Allergy Clin Immunol (2007) 1.88

Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol (2011) 1.88

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med (2012) 1.85

Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol (2013) 1.83

Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax (2010) 1.82

CT metrics of airway disease and emphysema in severe COPD. Chest (2009) 1.81

Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80

Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med (2014) 1.80

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79

Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. Am J Respir Crit Care Med (2011) 1.76

Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics (2003) 1.74

Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72

Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72